Abstract: This invention relates to the treatment of erectile dysfunction with a combination of (1) a compound selected from potassium channel openers, and (2) a compound selected from compounds which elevate cGMP levels. Sildenafil or a pharmaceutically acceptable salt thereof is preferred as the cGMP PDE elevator. Also included are compositions and kits comprising such impotence treating compounds.
Abstract: A “one-pot” process is described herein for the production of pyrazole compounds of general formula (II)
comprising the steps of reacting a compound of general formula (III)
with an acylating agent in the presence of a base and an optional activating agent followed by the addition of a hydrazine compound in situ.
Type:
Grant
Filed:
July 6, 2001
Date of Patent:
June 18, 2002
Assignee:
Pfizer Inc.
Inventors:
Laurence James Harris, Philip Charles Levett
Abstract: Isoxazole-sulfonamide endothelin antagonists of formula (I) below having good affinity for endothelin receptors and selectivity for ETA over ETB are described herein.
Such compounds are useful in the treatment of conditions mediated by endothelin, in particular, conditions mediated by endothelin ETA.
Type:
Grant
Filed:
May 30, 2001
Date of Patent:
May 14, 2002
Assignee:
Pfizer Inc.
Inventors:
Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Michael Stephen Pacey, Darren John Schulz
Abstract: NPY antagonists, methods of using such NPY antagonists and pharmaceutical compositions containing such NPY antagonists. The NPY antagonists are useful for the treatment of NPY mediated disease/conditions including obesity.
Type:
Grant
Filed:
March 31, 2000
Date of Patent:
March 12, 2002
Assignee:
Pfizer Inc.
Inventors:
Richard L. Elliott, Richard F. Hank, Marlys Hammond
Abstract: The invention relates anhydrous para-toluenesulphonic acid salts of 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy) pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo [4,3-d]pyrimidin-7-one having the formula (I):
a process for preparing compounds (I), pharmaceutical compositions containing (I) and use of (I) in medicine.
Abstract: A method for stabilizing blood pressure during hemodialysis is described which uses a phosphodiesterase inhibitor, in particular, a cGMP PDEv inhibitor in the treatment of humans.
Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
Type:
Grant
Filed:
January 6, 1999
Date of Patent:
December 5, 2000
Assignee:
Eli Lilly and Company
Inventors:
William J. Hornback, Scott C. Mauldin, John E. Munroe
Abstract: A method of inhibiting an envelope virus selected from the group consisting of influenza bovine diarrheal, hepatitis C and tick borne encephalitis virus that udergoes hemagglutinin-mediated fusion with a host cell is disclosed which comprises administering to a virus-infected cell, a cell susceptible of infection or a mammal in need thereof, an effective amount of a compound as defined by Formula I in the specification.
Type:
Grant
Filed:
January 6, 1999
Date of Patent:
October 3, 2000
Assignee:
Eli Lilly and Company
Inventors:
Joseph M. Colacino, William J. Hornback, Scott C. Mauldin, John E. Munroe, Joseph C. Tang
Abstract: The present invention provides compounds which inhibit. an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
Abstract: The present application provides a series of benzimidazole compounds of formula I: ##STR1## which inhibit the growth of picornaviruses, such as rhinoviruses (bovine and human), enteroviruses such as polioviruses, coxsackieviruses of the A and B groups, or echo virus, cardioviruses such as encephalomyocarditis (EMC), apthoviruses such as foot and mouth disease virus, and flaviviruses such as hepatitis C virus and bovine viral diarrhea virus.Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.
Type:
Grant
Filed:
October 22, 1999
Date of Patent:
September 5, 2000
Assignee:
Eli Lilly and Company
Inventors:
Steven Eugene Dunlap, Louis Nickolaus Jungheim, Mark Joseph Tebbe, Gilbert Thomas Voy, John Arnold Werner
Abstract: A82846-related glycopeptide compounds are prepared by treating an antibiotic selected from A82846 components A, B and C with trifluoroacetic acid to remove 1) the .alpha.-L-O-4-epi-vancosaminyl group attached to the disaccharide; 2) the (.alpha.-L-O-4-epi-vancosaminyl-.beta.-O-glucosyl) disaccharide group or 3) both the disaccharide group and the .alpha.-L-O-4-epi-vancosaminyl group attached to the peptide core from these antibiotics. The compounds have antibacterial activity, especially against Gram-positive microorganisms.
Type:
Grant
Filed:
December 21, 1993
Date of Patent:
August 29, 2000
Assignee:
Eli Lilly and Company
Inventors:
Manuel Debono, R. Michael Molloy, Ramakrishnan Nagarajan, Amelia A. Schabel
Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
Type:
Grant
Filed:
January 6, 1999
Date of Patent:
August 1, 2000
Assignee:
Eli Lilly and Company
Inventors:
William J. Hornback, Scott C. Mauldin, John E. Munroe
Abstract: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof. These compounds inhibit the growth of piconaviruses, such as rhinoviruses, Hepatitus viruses, cardioviruses, polioviruses, enteroviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus.
Type:
Grant
Filed:
July 2, 1999
Date of Patent:
July 11, 2000
Assignee:
Eli Lilly and Company
Inventors:
Kurt D. Schladetzky, Wayne A. Spitzer, Michael S. Vannieuwenhze
Abstract: Formulations and applications thereof are described which are useful for the inhibition of various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds represented by the following structure where X is a halogen.
Type:
Grant
Filed:
September 1, 1999
Date of Patent:
July 11, 2000
Assignee:
Eli Lilly and Company
Inventors:
George Joseph Cullinan, Brian Stephen Muehl, Kenneth Jeff Thrasher
Abstract: An improved and a new synthetic route for the reparation of spirocyclic C-glycoside compounds having the following general structure are described. ##STR1## Novel derivatives of spirocyclic C-glycoside compounds are also disclosed which may be used as intermediates in the synthesis and evaluation of potential pharmaceutically active materials.
Type:
Grant
Filed:
June 28, 1999
Date of Patent:
May 30, 2000
Assignee:
Eli Lilly and Company
Inventors:
Stephen Andrew Hitchcock, Chafiq Hamdouchi, Concepcion Sanchez-Martinez, Almudena Rubio Esteban